**Atopic Dermatitis/Eczema at the 2017 SID Annual Meeting**

*Updated April 10 2017*

(see full program details on [SID website](https://www.sid.org) for most current info)

**WEDNESDAY, April 26, 2017**

**8th Pan-Pacific Skin Barrier Symposium (PAPSBRS).** A105-106.

9:00 am – 4:30 pm

1:15 pm **Plenary Talk #4**, Dr. E.H. Choi (Yonsei U Wonju), Stratum corneum acidification and its potential clinical application

1:45 pm **Plenary Talk #5**, Dr. K. Kabashima (Kyoto U), Cutaneous biological responses to external stimuli

2:15 pm Platform #8, Dr. S.J. Choe (Yonsei U Wonju), 11beta-hydroxysteroid dehydrogenase 1 expression in the skin might have a role in the occurrence of AD

2:30 pm Platform #9, Dr. M. Kishibe (Asahikawa Med U), Incomplete secretion of KLK7 and upregulated LEKTI are related to hyperkeratosis in stratum corneum in AD

2:45 pm Platform #10, Dr. A. Lowe (U Melbourne, AU), A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: PEBBLES pilot study

3:15 pm **Plenary Talk #6**, Dr. R. Gallo (UC San Diego), Links between barrier function, S. aureus colonization, and Th2 inflammation

**Albert M. Kligman/Phillip Frost Leadership Lecture.** Oregon Ballroom 201-202.


---

**THURSDAY, April 27, 2017**

**Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology.** Rooms A105 & A106

7:00–8:00 am: *Pediatric Dermatology at the SID.*

**Selected ePoster Discussions I: Moderator Jonathan Silverberg.** Exhibit Hall A Foyer 11:03 am #382 Adult-onset atopic dermatitis is associated with a distinct phenotype. *P. Vakharia, R. Chopra, R. Sacotti, N. Patel, S. Immaneni, R. Kantor, D. Hsu, J. Silverberg.*

12:00 pm Welcome and Introduction, John Harris, MD/PhD

12:05 pm Getting to know JAKs, Paul Changelian, PhD

12:15 pm JAKs be nimble: Building a Better Inhibitor, Jon Jacobsen, PhD

12:45 pm Scratch that Itch: JAK Inhibitors in Pruritus, Brian S. Kim, MD/MTR

1:05 pm JAK hammers: Topical Delivery for JAK Inhibitors, Vijendra Nalamothu, PhD

1:30 pm Panel Discussion and Q&A with Presenters

2:00 pm #640 Enhancement of Th2 polarization by Trim32 deficiency. Y. Liu, Z. Wang, R. De La Torre, A. Barling, N. Hornick, J. Hanifin, E. Simpson and M. Kulesz-Martin.

2:12 pm #624 PSMα as a key virulence in Staphylococcus aureus-induced skin inflammation through IL-36 and IL-1 release from keratinocytes. S. Nakagawa, Y. Nakamura, G. Nunez and H. Matsue. Chiba

2:24 pm #557 Microbiome controls mast cell differentiation in the skin. Z. Wang, N. Mascarenhas, L. Eckmann, Y. Miyamoto, X. Sun, T. Kawakami and A. Di Nardo.

2:36 pm #439 Mutations in the epidermal fatty acid and ceramide metabolic pathway reveal functions of the Corneocyte-Bound Lipid Envelope (CLE). Elias, M. Man and D. Crumrine.


3:24 pm #625 Differential diversity of staphylococcal strains shapes cutaneous response in atopic dermatitis. A. Byrd, C. Deming, S. Cassidy, O. Harrison, W. Ng, S. Conlan, Y. Belkaid, J. Segre and H. Kong.

3:36 pm #313 A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb. E. Guttmann-Yassky, S. Khattri, PM. Brunner, A. Neumann, K. Malik, J. Fuentes-Duculan, S. Garce, M. Suarez-Farinas,


CONCURRENT MINI-SYMPOSIUM 2: Clinical Research: Pathophysiology and Therapeutics Including studies involving human tissue and human cells that furthers our understanding of skin disease. Oregon Ballroom 203

IEC Councillor’s meeting (IEC Councilors and Associates only). Rooms B117-119.
4:40 – 6:10 pm TOPIC: Management of the Itch of AD.

FRIDAY, April 28, 2017

Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology. Rooms A105 & A106.
7:00–8:00 am Pediatric Dermatology at the SID.

PLENARY SESSION II: Oregon Ballroom 201-202.
8:36 am #197 Influence of FLG mutations and TSLP polymorphisms on atopic dermatitis onset age. J. Wan, N. Mitra, OJ. Hoffstad and DJ. Margolis.

9:00 – 9:15 am. Amy Paller, IEC President

Come See My Poster II: Oregon Ballroom 201-202
International Eczema Council (IEC)
12:00-1:30 pm  Oregon Ballroom 204
(Lunch served, free registration recommended at www.eczemacouncil.org).

12:00 pm Welcome/Overview of the IEC and Roadmap of AD at the SID Amy Paller

12:10-12:45 pm Abstract Presentations

#256: Increased interleukin-19 expression in cutaneous T-cell lymphoma as well as atopic dermatitis. Oka Tomonori et al. Univ. of Tokyo, Tokyo, Japan

#623: Cutaneous acquisition of Staphylococcus quorum-sensing agr mutations protects against atopic dermatitis development. Yuumi Nakamura et al., Chiba Univ., Chiba, Japan

#642: The serum proteomic signature of pediatric AD suggests early Th2/Th17 skewing and an inverse correlation of disease severity with Th1 markers. Patrick Brunner et al. Rockefeller Univ., New York, NY, USA

12:45 pm Special Presentation: The precise control of skin barrier homeostasis Masayuki Amagai, Keio University, Tokyo, Japan

1:10-1:30 pm Abstract Presentations

#296: Bleach baths promote early induction of inflammatory pathway genes with no effect on skin bacterial dysbiosis in AD subjects. Sara Knowlden et al., Univ. of Rochester, Rochester, NY, USA

#251: Treatment interruption did not impact efficacy or long-term safety of dupilumab: A phase 3 open-label trial. Lisa Beck et al. Univ. of Rochester, Rochester, NY, USA

Selected ePoster Discussions II: Moderator: Robert Dellavalle. Exhibit Hall A Foyer

Selected ePoster Discussions II: Moderator: Theodora Mauro. Exhibit Hall A Foyer
12:00 pm #636 Commensal skin bacteria inhibit the capacity of Staphylococcus aureus to induce epidermal serine protease activity in atopic dermatitis. M. Williams, T. Nakatsuji, R. Gallo.
12:42 pm #438 Activation of protease-activated receptor 2 leads to impairment of keratinocyte differentiation and tight junction integrity. M. Henehan; P. Nadeau; A. DeBenedetto.

1:00 pm #243 Real world systemic corticosteroid (SCS) utilization patterns and costs in adult patients with atopic dermatitis. A. Armstrong, W. Wei, R. Miao, M. Patel, A. Huang, L. Wand, J. Chao.
CONCURRENT MINI-SYMPOMATIC 6: Clinical Research: Patient Outcomes Research Includes meta-analysis of interventional trials, and patient outcomes research. Oregon Ballroom 204

3:00 pm #383 Establishing severity strata for 5 different patient-reported outcomes in adults with atopic dermatitis. R. Sacotte, P. Vakharia, R. Chopra, N. Patel, S. Immaneni, T. White, R. Kantor, D. Hsu, E. Simpson and J. Silverberg.

CONCURRENT MINI-SYMPOMATIC 7: Genetic Disease, Gene Regulation and Gene Therapy Studies on cutaneous gene expression and genetic diseases including gene therapy. B113-116
2:24 pm #495 Ichthyosis molecular fingerprinting shows profound Th17-skewing and a unique barrier gene expression pattern. H. He, T. Huynh, E. Ibler, K. Malik, G. Tran, H. Esaki, JG. Krueger, AS. Paller and E. Guttman-Yassky.

3:48 pm #492 SNPs within the MHC associated with atopic dermatitis are located within miRNA sequences. P. Clark, N. Chitnis, M. Kamoun, B. Johnson, Dj. Margolis and D. Monos.

CONCURRENT MINI-SYMPOMATIC 8: Innate Immunity, Microbiology, Inflammation Studies of cells, receptors and effector molecules of the innate immune response; studies on skin microbes and infectious processes of the skin. Oregon Ballroom 203

IEC Industry Liaison Meeting (invite only–email mjung@eczemacouncil.org)
4:45-5:30 pm IEC Update. Room B11

Introducing a New Topical Prescription Treatment Option for Atopic Dermatitis (Pfizer): Oregon Ballroom 201-202
5:00 pm – 5:45 pm. Lawrence Eichenfield, MD  Professor of Dermatology and Pediatrics

National Eczema Association Reception
6:00-7:00 pm, A105-106

SATURDAY, April 29, 2017

Come See My Poster III: Oregon Ballroom 201-202
10:03 am #421 Elevated serum IgE level, but not TARC and LDH, may reflect the impairment of stratum corneum barrier function in healthy individuals; Results of cross-sectional study of 1141 Japanese healthy individuals. E. Akasaka, K. Hara, M. Takahashi, T.

**Selected ePoster Discussions III: Moderator: Masayuki Amagai.** Exhibit Hall A Foyer 10:45am #001 Malat1 drives differentiation of memory CD8+ T cells. *N. Carter et al.*

**CONCURRENT MINI-SYMPOTIUM 12: Clinical Research: Epidemiology of Skin Diseases**

Oregon Ballroom 203


1:06 pm #198 Black children less likely to receive outpatient care for eczema than whites, but show signs of more severe disease: A cross-sectional analysis of the medical expenditure panel surveys. *D.B. Shin, A.H. Fischer, D.J. Margolis and J. Takeshita.*


**CONCURRENT MINI-SYMPOTIUM 15: Pharmacology and Drug Development**

**Basic and preclinical studies aimed at developing therapeutics, elucidating their mechanisms of action, and identifying biomarkers of drug activity.** 105-106


**POSTERS NOT BEING PRESENTED ORALLY**

#038 Hyaluronan oligosaccharides induce suppressive effect to chronic allergic dermatitis. *J. Muto et al.*

#058 Non-lesional atopic dermatitis skin shares similar T cell clones with lesional tissues. Brunner P, *R. Emerson et al.*

#073 Th17 and Th22 polarization in ichthyosis blood correlates with disease severity and highlights its systemic nature. *T. Czarnowicki et al.*

#080 IL-9 promotes Th responses in epicutaneous sensitization with protein antigens. *L. Wang et al.*

#082 Systemic atopic dermatitis has different immune signatures. *J. Lee et al.*

#153 Topical corticosteroid phobia and fear in atopic dermatitis: A systematic review. *A. Li et al.*

#173 Systematic review of atopic dermatitis disease definitions in routinely-collected health data. *M. Dizon et al.*


Atopic dermatitis is associated with increased risk of serious infections in US children and adults. *S. Narla et al.*

The prevalence of eczema beyond childhood: A systematic review and meta-analysis of longitudinal studies. *A. Yu et al.*

New nonsynonymous variants of SPINK5 gene in Japanese atopic dermatitis patients. *S. Morizane et al.*

Risk of contraindication and drug-drug interaction (DDI) with use of systemic immunosuppressants (IMMs) in adult patients with atopic dermatitis (AD). *A. Armstrong et al.*

Increased interleukin-36γ expression in skin and sera of patients with atopic dermatitis and cutaneous T-cell lymphoma. *S. Otobe et al.*


RNA-seq profiling highlights the robust inflammation and Th17-skewing of the non-lesional Asian atopic dermatitis phenotype. *H. Wen et al.*

Collagen tripeptide may modulate inflammation in atopic dermatitis. *A. Hakuta et al.*

Standardizing the diagnostic criteria used for atopic dermatitis: a systematic review. *P. Vakharia et al.*


Comparison of EASI and objective-SCORAD assessments in adult atopic dermatitis. *R. Chopra et al.*

Profiling of epidermal lipids to identify potential biomarkers of atopic dermatitis. *J. Franco et al.*


Air exposure and dehydration down-regulates EGFR and Aquaporin 3 in cultured human skin keratinocytes. *W Zhang et al.*
#417 A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: The PEBBLES pilot study. A. Lowe et al.

#420 The effects of bathing, showering and petrolatum on skin barrier function. E. Bolton et al.

#429 The ratio of sphingosine to sphinganine in the stratum corneum determines lipid lamellar structure packing. Y Obata et al.

#430 IFN-γ may disrupt skin barrier function through reduction of long-chain fatty acid ceramides in mite-induced dermatitis. H. Kanoh et al.

#437 A suitable Raman microspectroscopy data processing: the key to understand atopic dermatitis in vivo at the molecular level. L. Verzeaux et al.

#444 Reactive oxygen species induce Th2 allergic inflammation in the skin by activating PI3K-HIF-α pathway. J. Choi et al.

#446 Early atopic dermatitis biological analysis. G Bellemere et al.

#533 Array-based sequencing of filaggrin gene for comprehensive detection of disease-associated variants. C. Wong et al.

#583 Atopic keratoconjunctivitis spontaneously develop in a mouse model of atopic dermatitis expressing the mouse interleukin-33 gene driven by a keratin 14 promoter. Y. Imai et al.

#587 Identification of IL-4 regulated microRNAs in primary keratinocytes. L. Bao et al.

#593 Staphylococcal enterotoxin B modifies ovalbumin-induced innate immune responses and skin inflammation in a murine model of atopic dermatitis. S. Fassbender et al.

#598 Increased expression of TRPV3 and TRPV4 channel in keratinocytes under Th2 inflammation. H. Ko et al.

#617 Basophils release amphiregulin and may contribute to murine models of prurigo reaction and MC903-induced atopic dermatitis-like skin inflammation. T. Hashimoto et al.

#620 Possible involvement of interleukin-33 and basophils in the pathophysiology of human atopic dermatitis via ST2 receptor. Y. Nonomura et al.

#656 Changes of lesional and non-lesional skin microbiome in the treatment course of atopic dermatitis. J. Na et al.

#676 Fluorescence lifetime imaging microscopy (FLIM) as a novel method to assess skin residency of a fluorescent compound: experience with GSK2894512. A. Alex et al.

#691 The effects of RVT-501 on DNBC-induced atopic dermatitis in NC/Nga mice. R. Roeloffs et al.
#693 Dust mite potently activates Th17/Th22 pathways and models multiple inflammatory skin conditions in humans. *K. Malik et al.*

#695 Topical application of KPI-150, a potent inhibitor of Kv1.3 channels on effector memory T cells, demonstrates preclinical efficacy in atopic dermatitis model. *C. Olsen et al.*


#898 Homeostatic activation of epidermal HSD11b1 affects skin innervation and non-histaminergic itch. *A. Matsumoto et al.*